Track EyePoint Pharmaceuticals's current cash ($110M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
EyePoint Pharmaceuticals (EYPT) currently reports a current cash of $110M as of June 2026. That compares with $71M in the prior-year period — up 55.3% year over year. Use the charts on this page to explore EyePoint Pharmaceuticals's current cash history and peer comparisons.
EyePoint Pharmaceuticals's current cash increased from $71M to $110M — a 55.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
EyePoint Pharmaceuticals reported $110M in current cash as of June 2026. That compares with $71M in the prior-year period — up 55.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current current cash of $110M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for EyePoint Pharmaceuticals, and consider following EYPT for alerts when major investors trade the stock.
EyePoint Pharmaceuticals is classified in the Healthcare sector. On current cash, it currently shows $110M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EYPT with unrelated industries.